Venture(US:VEMLY) Sou Hu Cai Jing·2026-01-20 09:59Core Viewpoint - Zeling Bio has submitted its IPO application to the Hong Kong Stock Exchange, marking its official attempt to go public [1] Group 1: Company Overview - Zeling Bio, founded in 2019, is an innovative biotechnology company focused on late-stage clinical development [4] - The company was incubated under the incentive policies for technology transfer from Sichuan University West China Hospital [2] - The founder, Dr. Chen Lijuan, has extensive experience in the biotechnology industry and holds multiple degrees in chemistry and pharmacy [4][6] Group 2: Financial Information - Zeling Bio recently completed a C-round financing of nearly 600 million RMB, led by Daming Capital and Qiming Venture Partners, bringing its valuation to approximately 3.411 billion RMB [2][8] - The company has raised a total of about 1.18 billion RMB across five financing rounds since its inception [8] - Financial data shows that Zeling Bio reported a net loss of 91.656 million RMB for the fiscal year 2024, with losses expanding to 119.043 million RMB in the first three quarters of 2025 [12][13] Group 3: Product Pipeline - The company has a pipeline of eight products, including two core products in Phase III clinical trials and two candidates in clinical stages [11] - The lead product, Fluorotinib, is aimed at treating myeloproliferative neoplasms, with plans to submit a new drug application to the National Medical Products Administration in 2027 [11][10] - Zeling Bio has not yet commercialized any products and has not generated revenue from product sales [12]